Company Overview
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Why Investors Should Care
Generates a return on equity of 21.7%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 22.3%.
Net profit has compounded at 15.1% per year over the last five years.
Trades at a P/E of 23.9, below the sector median of 25.2.
Operating margin of 20.3% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.17.
Recent Developments
- Jun 2025 Revenue of $64.00M (+17.0% YoY); net profit $7.54M.
- Trailing 12 Months Year-on-year growth — revenue +18.4%, earnings +66.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.1%, profit CAGR 15.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.06% |
| 1 Year: | 18.40% |
Compounded Profit Growth
| 5 Years: | 15.07% |
| 1 Year: | 66.70% |
Stock Price Performance
| 1 Year: | +41.92% |
| 6 Months: | +17.25% |
| 3 Months: | -25.71% |
| 1 Month: | -33.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)23.73 · Oversold
P/E of 23.93 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 21.7%.
- Healthy ROCE of 22.3%.
- Profit CAGR of 15.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 39.5% below its 52-week high.
- RSI at 24 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELMD Electromed, Inc. R2KPHARMA | 28.00 | 23.93 | $231.84M | 0.00% | 22.29% | 21.70% | 9.06% | 15.07% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.30M | 6.96M | 7.17M | 7.28M | 8.01M | 7.41M | 8.30M | 8.55M | 8.74M | 8.00M | 9.50M | 8.79M | 10.00M | 10.25M | 10.14M | 10.66M | 11.73M | 12.07M | 12.32M | 13.69M | 13.87M | 14.67M | 16.25M | 15.68M | 16.89M | 18.90M | 18.57M |
| Gross Profit | 2.44M | 2.36M | 2.52M | 2.52M | 3.29M | 3.40M | 3.16M | 3.86M | 4.90M | 4.63M | 4.33M | 4.93M | 5.31M | 4.69M | 5.40M | 5.51M | 5.54M | 6.06M | 5.57M | 6.34M | 6.68M | 6.59M | 6.15M | 7.53M | 6.70M | 7.70M | 7.88M | 7.74M | 8.33M | 8.68M | 9.06M | 9.50M | 10.54M | 10.38M | 11.49M | 12.63M | 12.23M | 13.20M | 14.82M | 14.64M |
| Operating Income | -693.81K | -577.20K | -308.79K | -217.06K | 397.98K | 447.39K | 57.58K | 585.17K | 1.25M | 735.69K | 288.88K | 729.46K | 1.04M | 99.15K | 770.65K | 577.82K | 201.71K | 675.00K | 464.55K | 1.35M | 1.57M | 913.10K | 663.00K | 1.58M | 243.00K | 538.00K | 1.08M | 863.00K | 44.00K | 1.27M | 1.20M | 142.00K | 2.26M | 1.84M | 1.94M | 2.54M | 2.14M | 2.67M | 3.62M | 3.77M |
| Net Income | -430.97K | -335.40K | -239.26K | -1.00M | 377.53K | 422.71K | 37.23K | 340.96K | 1.07M | 466.62K | 191.17K | 443.86K | 647.95K | 80.95K | 419.76K | 376.49K | 157.16K | 380.52K | 352.93K | 1.01M | 1.19M | 653.27K | 535.00K | 1.20M | 224.00K | 439.00K | 838.00K | 645.00K | 81.00K | 977.00K | 1.07M | 155.00K | 1.67M | 1.49M | 1.47M | 1.97M | 1.89M | 2.14M | 2.76M | 3.00M |
| Diluted EPS | -0.05 | - | -0.03 | -0.12 | 0.05 | 0.05 | 0.00 | 0.04 | 0.13 | 0.06 | 0.02 | 0.05 | 0.08 | 0.01 | 0.05 | 0.04 | 0.02 | 0.04 | 0.04 | 0.12 | 0.14 | 0.07 | 0.06 | 0.13 | 0.03 | 0.05 | 0.10 | 0.07 | 0.01 | 0.11 | 0.12 | 0.02 | 0.19 | 0.17 | 0.16 | 0.22 | 0.21 | 0.25 | 0.32 | 0.35 |
| R&D Expense | 101.46K | 209.11K | 92.73K | 103.17K | 75.27K | 83.64K | 78.29K | 41.54K | 57.09K | 84.41K | 350.84K | 100.80K | 80.61K | 70.66K | 56.79K | 42.66K | 68.19K | 237.84K | 170.76K | 98.94K | 143.48K | 391.96K | 481.00K | 507.00K | 407.00K | 376.00K | 329.00K | 336.00K | 298.00K | 154.00K | 166.00K | 206.00K | 107.00K | 167.00K | 166.00K | 251.00K | 277.00K | 241.00K | 384.00K | 361.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.00M | 19.52M | 15.10M | 15.49M | 19.41M | 22.99M | 25.86M | 28.31M | 31.30M | 32.47M | 35.76M | 41.66M | 48.07M | 54.72M | 64.00M |
| Gross Profit | 13.78M | 14.15M | 10.45M | 10.63M | 13.60M | 17.88M | 20.57M | 21.77M | 23.85M | 25.20M | 27.30M | 31.44M | 36.52M | 41.73M | 49.97M |
| Operating Income | 1.87M | 606.34K | -1.83M | -740.59K | 1.31M | 3.11M | 3.57M | 2.71M | 2.83M | 5.12M | 3.14M | 2.97M | 4.01M | 6.58M | 9.66M |
| Net Income | 1.06M | 186.61K | -1.33M | -1.29M | 1.09M | 2.21M | 2.23M | 1.83M | 1.98M | 4.16M | 2.36M | 2.31M | 3.17M | 5.15M | 7.54M |
| Diluted EPS | 0.13 | 0.02 | - | -0.16 | 0.13 | 0.27 | 0.26 | 0.21 | 0.23 | 0.47 | 0.27 | 0.26 | 0.36 | 0.58 | 0.85 |
| R&D Expense | 1.03M | 920.77K | 603.38K | 466.06K | 315.65K | 380.39K | 596.88K | 251.44K | 583.31K | 1.05M | 1.72M | 1.36M | 916.00K | 656.00K | 996.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 20.87M | 20.92M | 17.56M | 15.79M | 17.41M | 20.58M | 23.06M | 27.39M | 29.40M | 33.24M | 37.11M | 41.36M | 45.81M | 52.23M | 53.80M |
| Total Equity | 7.46M | 14.71M | 15.08M | 13.93M | 12.72M | 13.92M | 16.36M | 19.83M | 22.58M | 25.73M | 30.25M | 32.42M | 34.17M | 37.67M | 44.55M | 43.21M |
| Cash & Equivalents | 610.73K | 4.09M | 1.70M | 503.56K | 1.50M | 3.60M | - | - | - | - | 10.48M | 11.89M | 8.15M | 7.37M | 16.08M | 15.29M |
| Long Term Debt | - | 1.58M | 1.39M | 1.33M | 1.25M | 1.20M | 1.15M | 1.10M | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 6.16M | 5.84M | 3.63M | 3.07M | 3.48M | 4.22M | 3.99M | 4.74M | 3.67M | 3.00M | 4.69M | 7.19M | 8.14M | 7.69M | 10.59M |
| Current Liabilities | - | 4.41M | 4.17M | 2.19M | 1.82M | 2.28M | 3.07M | 2.90M | 4.80M | 3.65M | 2.99M | 4.64M | 7.15M | 8.05M | 7.68M | 10.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.42M | -1.17M | - | - | - | 2.17M | 1.19M | 2.44M | 2.59M | 4.20M | 3.08M | -686.00K | 1.31M | 9.07M | 11.39M |
| Investing Cash Flow | -1.11M | -848.75K | - | - | - | -579.52K | -687.15K | -571.78K | -1.39M | -977.00K | -448.00K | -1.52M | -1.72M | -395.00K | -306.00K |
| Financing Cash Flow | 6.01M | -368.78K | - | - | -61.17K | -62.27K | -53.62K | 11.71K | -851.15K | -548.00K | -1.22M | -1.52M | -380.00K | 36.00K | -11.88M |
| Capital Expenditure | -466.31K | -791.55K | -1.02M | -895.18K | -523.18K | -534.94K | -618.76K | -526.23K | -1.33M | -844.00K | -287.00K | -1.43M | -1.65M | -287.00K | -262.00K |
| Free Cash Flow | -1.88M | -1.96M | - | - | - | 1.63M | 572.36K | 1.92M | 1.26M | 3.35M | 2.79M | -2.11M | -333.00K | 8.78M | 11.13M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 1.12M | 1.45M | 153.00K | 275.00K | 10.00M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 72.5% | 72.4% | 69.2% | 68.7% | 70.1% | 77.7% | 79.5% | 76.9% | 76.2% | 77.6% | 76.4% | 75.5% | 76.0% | 76.3% | 78.1% |
| Operating Margin % | 9.8% | 3.1% | -12.1% | -4.8% | 6.8% | 13.5% | 13.8% | 9.6% | 9.0% | 15.8% | 8.8% | 7.1% | 8.3% | 12.0% | 15.1% |
| Net Margin % | 5.6% | 1.0% | -8.8% | -8.3% | 5.6% | 9.6% | 8.6% | 6.5% | 6.3% | 12.8% | 6.6% | 5.5% | 6.6% | 9.4% | 11.8% |
| ROE % | 7.2% | 1.2% | -9.5% | -10.1% | 7.8% | 13.5% | 11.2% | 8.1% | 7.7% | 13.8% | 7.3% | 6.7% | 8.4% | 11.6% | 17.4% |
| ROCE % | 11.4% | 3.6% | -11.9% | -5.3% | 8.7% | 17.8% | 17.7% | 12.0% | 11.0% | 16.9% | 9.7% | 8.7% | 10.6% | 14.8% | 22.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | J.e. Simmons & Co., P.c. | 5.78% | 483.82K | $14.32M |
| 2 | Blackrock Inc. | 5.57% | 465.62K | $13.78M |
| 3 | Vanguard Capital Management LLC | 3.39% | 283.23K | $8.38M |
| 4 | Acadian Asset Management. LLC | 2.65% | 221.84K | $6.57M |
| 5 | Punch & Associates Investment Management, Inc. | 2.61% | 218.52K | $6.47M |
| 6 | Geode Capital Management, LLC | 2.60% | 217.12K | $6.43M |
| 7 | Dimensional Fund Advisors LP | 2.16% | 180.45K | $5.34M |
| 8 | Two Sigma Investments, LP | 2.00% | 167.49K | $4.96M |
| 9 | Hunter Associates Investment Management LLC | 1.86% | 155.88K | $4.61M |
| 10 | Gamco Investors, Inc ET AL | 1.70% | 142.00K | $4.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELMD
Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNSWFiV3VFSDVlNVNHbHpKVUtaU1ZHOGxXQkxpc1FHajh3ZWQ0akNZTlJ5UUdMV1JjV2NiRWpXS2dfdkF1enk3YVBaVkU3Tzdua1VyM1FaRHYtbDJTTjROVzBSQ05EeXBFdVlibnFpbVlwcExfWFZrR1VFTERzMDJmeUZIZ3R2X3JYclZMVU…
Electromed (ELMD) Stock Reprices As Hospital Weakness Clouds Growth Story - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPaU1oOGRjZV9MTUZkenY4bGtKY1FZYjY4dzBaTWJnWmN3SGFfWFEtYnZvT3FWaGZzdE1fYmJ3R1Y4dG5BcEppMmdFTC1rc201MWFJZWNxUTRRdGZxOFBnMnk5cU1Fc3F3Z2RacEVBaFhvQnltdlViNEQzSmJjWS1qWmNrVnRCN1VyZHcwSE…
$ELMD stock is down 13% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNRWRSS2hjdlRqS3gtX3loZXdyVS0ySV80R3pyMkNRVWpzSFJGWUVDMktEX3ZrQmR6dFNQZFh6eDB3YXlTajUxWmlINGlITW90ZTQ3cDU4V2hDUGlUcUQ0VjY4dGdHb2xqcVpGQWE3Qi03RHNnUS01WjdqM0NKS0RUeHVZR0FwVmJPQk8wVV…
Electromed CEO expects to retire after 15 straight quarters of revenue and profit growth - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOdVBGQUU0OFJnemkyUGZEY2x0dkdEU2drTWYtTTRRRHBDU3RGWm50cDFhMms5TlB0dk9yUFdVQWQtZ3BEbjktcDZKUUN3NGJaMi1FMkdRNk42bEFkVUhlMVRaMkVodXhLeFRVZC0yRTBnbnNhM3RIZXNYbldpZk5HZTd4R3g0VkJhb1FrMW…
Electromed (ELMD) is an Incredible Growth Stock: 3 Reasons Why - qz.com
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9DYy1YMGZVSTAxNHREdkRoZUhEM3BEblRETGlVcEdSSDNzTUtFYm56ZUFPclFYRjRLMGVlNG9YSFAzcEVZSEhwdEpwTG9GdzJROGtGaEl3UVFua08taXdYYm5iOFoyd0Q2Q3k4dTdFdkRNRmtKdk1DZGI2X2V4OFk?oc=5" target="_bla…
Stocks to watch on Tuesday after hours: SMTC, ELMD, ZM (SMTC:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNeF9FSFZrS1YxZXVBcTFDWDN1aFg1U3pSZVl6YTJzem1ydkIyWnRLcmh3ZkplQmRUd3cyVFNFVnFTemt3YmF4b3k0dkxrQUJScE45REhJamZuX3hXQmk4VVNNTzR6Wk5IbThLZ0JDQUhYdER3bEk3TzFDWlA1SFpjUC1oZ3N6YzBkRmdpcD…
ELMD — Frequently Asked Questions
What is the current share price of Electromed, Inc. (ELMD)?
As of 2026-09-07 16:24 PDT, Electromed, Inc. (ELMD) trades at $28.00 on NYSE American. Its 52-week range is $18.93 to $46.31.
What is the market capitalisation of ELMD?
Electromed, Inc. (ELMD) has a market capitalisation of $231.84M on NYSE American.
What is the P/E ratio of ELMD?
ELMD trades at a trailing price-to-earnings (P/E) ratio of 23.93. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.11.
What is the return on equity (ROE) of ELMD?
ELMD has a return on equity (ROE) of 21.70%. Its return on capital employed (ROCE) is 22.29%.
Is ELMD a good stock to buy?
This page provides a data-driven analysis of Electromed, Inc. (ELMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.